>> Are you expecting them to run the PIII as the dosing trial? Pharma doesn't like to do that. They like their ducks all in a row by the time they get to the pivotal trials. <<
Eyetech tested three doses in each of their phase-3 Macugen trials, so it can be done.
Squalamine’s dose for AMD is pretty well set at 25mg/m2. What is still malleable is the dosing interval to be used following the initial loading regimen of four weekly infusions.
Apropos to the discussion about Allergan’s Tazarotene and the discussion about systemic treatments for localized conditions, here is an update on Tazarotene treatment for psoriasis:
Market Data 
Markets 
AI
